Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
22 June 2017

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Why we need to re-focus on Latin AmericaRead more...

In March 2014, the Residual Risk Reduction Initiative (R3i) extended its mission to Latin America, recognizing the specific challenge of cardiometabolic disease in this region, a direct consequence of escalating rates of obesity and diabetes.
This approach was in response to accumulating evidence that atherogenic dyslipidaemia was a key issue.
 
For example, the Carmela study showed that the prevalence of dyslipidaemia was high albeit variable in seven Latin American countries, ranging from 75% in men in Barquisimeto to 24% in women in Buenos Aires...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
22 June 2017

Proof of concept: ANGPTL3 deficiency protects against coronary artery disease Read more...

ANGPTL3 decreases triglyceride-rich lipoproteins through by inhibition of lipoprotein lipase. As highlighted in previous reports on the R3i website, ANGPTL3 has been mooted as a potential therapeutic target for managing elevated triglycerides.  The support for this proposal is based on mechanistic studies showing that ANGPTL3...
focus on...
22 June 2017

Position paper on atherogenic dyslipidaemia in Latin America Read more...

While risk factors for cardiovascular disease are the same for men and women globally, their presentation in different regions of the world varies. Latin America is distinct from other regions in that there is a higher prevalence of abdominal obesity, hypercholesterolaemia and hypertension.3 On average,...
recent publication

Does road traffic noise/air pollution play a role in cardiometabolic disease risk?Read more...

The results from this study based on data from two...
recent publication

Atherogenic dyslipidaemia is predictive of incident CHD in ChinaRead more...

This Chinese study highlights the importance of triglycerides and high-density...
recent publication

Are triglycerides causal in cardiovascular disease?Read more...

Insights from genetic studies have proved critical in investigating the...
recent publication

Remnant lipoproteins and cardiovascular riskRead more...

This new review discusses recent advances in the field of...
recent publication

Is FGF21 a potential target in hypertriglyceridaemia?Read more...

Fibroblast growth factor 21 (FGF21) is a key mediator of...
recent publication

Is inflammation a key determinant of the atherogenicity of remnant cholesterol?Read more...

Attention has refocused on remnant cholesterol, transported by triglyceride-enriched precursors...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.